Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Cost of Revenue (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Cost of Revenue data on record, last reported at $41.3 million in Q3 2025.

  • For Q3 2025, Cost of Revenue rose 12.27% year-over-year to $41.3 million; the TTM value through Sep 2025 reached $157.8 million, changed N/A, while the annual FY2025 figure was $167.5 million, 9.77% up from the prior year.
  • Cost of Revenue reached $41.3 million in Q3 2025 per CAI's latest filing, down from $42.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $42.3 million in Q2 2025 and bottomed at $36.8 million in Q3 2024.